Hongene Biotech Seeks Pre-IPO Funds at $6 Billion Value, Sources Say
- Shanghai-based firm could raise $400 million in pre-IPO round
- Hongene is exploring Hong Kong IPO as soon as next year
This article is for subscribers only.
Hongene Biotech Corp. is weighing a new funding round that could value the Chinese synthesis blocks and enzymes maker at about $6 billion, people familiar with the matter said.
The Shanghai-based company is working with advisers on the fundraising, which could raise about $400 million, said the people, who asked not to be identified as the information is private.